Article info
PDFClinical and epidemiological research
Preferential decrease in IgG4 anti-citrullinated protein antibodies during treatment with tumour necrosis factor blocking agents in patients with rheumatoid arthritis
- Dr W H Bos, Department of Immunopathology, Sanquin Research, PO Box 9190, 1006 AD Amsterdam, The Netherlands; w.bos{at}sanquin.nl
Citation
Preferential decrease in IgG4 anti-citrullinated protein antibodies during treatment with tumour necrosis factor blocking agents in patients with rheumatoid arthritis
Publication history
- Accepted April 24, 2008
- First published April 29, 2008.
Online issue publication
September 19, 2019
Article Versions
- Previous version (19 September 2019).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
2009 BMJ Publishing Group and European League Against Rheumatism